ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2406

Risk of Large Vessel Complications in Patients with Giant Cell Arteritis, a Population-based Study

Mohanad Elfishawi1, Mahmut Kaymakci1, Sara Achenbach2, Cynthia Crowson1, Tanaz Kermani3, Cornelia M. Weyand4, Matthew Koster1 and Kenneth Warrington1, 1Mayo Clinic, Rochester, MN, 2Mayo Clinic, Rochester, MN, Rochester, MN, 3University of California Los Angeles, Los Angeles, CA, 4Mayo Clinic School of Medicine and Stanford University, Rochester, MN

Meeting: ACR Convergence 2023

Keywords: Epidemiology, giant cell arteritis, Mortality, population studies, Vasculitis

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Tuesday, November 14, 2023

Title: (2387–2424) Vasculitis – Non-ANCA-Associated & Related Disorders Poster III

Session Type: Poster Session C

Session Time: 9:00AM-11:00AM

Background/Purpose: Large vessel (LV) complications are known to occur in patients with giant cell arteritis (GCA). The magnitude of risk compared to the general population remains unclear.
In this study, we aimed to estimate the incidence of LV manifestations in a population-based cohort of patients with GCA compared with a non-GCA cohort from the same population.

Methods: The patient cohort included cases with incident GCA between 2000-2016 in defined geographical area. Incident LV complications were defined as aortic aneurysm, aortic dissection, stenosis in the aorta or any of its main branches diagnosed within 1 year prior to the diagnosis of GCA or anytime afterwards. A comparator cohort (age- and sex- matched) of individuals without GCA was assembled from the same population. Each subject was given an index date corresponding to an incidence date in the GCA cohort. All subjects were followed through December 31st, 2020, death, or migration. Cumulative incidence of large artery complications was adjusted for the competing risk of death. Cox proportional hazards models were used to assess the association of clinical characteristics with large artery complications.

Results: The patient cohort included 119 cases with GCA. Majority were female (88, 74%); mean age at diagnosis was 77.7 ± 8.1 years. Mean follow up for GCA cohort was 8.9 ± 4.7 years and 7.7 ± 4.9 years for the comparator cohort. LV complications occurred in 49 patients in the GCA cohort Vs 20 in non-GCA (HR: 2.67, 95% CI: 1.59-4.51). Large artery stenosis occurred in 40 patients in GCA cohort vs. 14 in non-GCA (HR: 2.98, 95% CI: 1.62-5.48). This included subclavian artery stenosis (17/40 GCA vs 1/14 non-GCA), axillary artery stenosis (9/40 GCA vs 0 non-GCA), vertebral artery stenosis (13/40 GCA Vs 3/14 non-GCA) and carotid artery stenosis (6/40 GCA Vs 4/14 non GCA).

On the other hand, aortic aneurysm/dissection occurred in 16 patients in the GCA cohort vs. 6 in non-GCA (HR: 2.41, 95% CI: 0.94-6.18). Furthermore, GCA was found to be a significant risk factor for the development of thoracic aortic aneurysm (HR: 13.46, 95% CI:1.78-101.98) but not for abdominal aortic aneurysm (HR: 1.08, 95% CI: 0.33-3.55) (Table 1). This elevated risk for any LV complication, large-artery stenosis and aneurysms persisted even when adjusted for age, sex, and comorbid conditions (Table 1). Interestingly, the incidence rates of any LV complication at 5 and 15 years were 27.8% (95% CI: 20.8-37.2%) and 49.2% (95% CI: 39.3-61.7%) respectively for the GCA cohort compared to 11.2% (95% CI: 6.7-18.7%) and 19.2% (95% CI: 12.5-29.4%) in the comparator cohort (Figure 1). Among individuals who developed LV complications, presence of GCA was not a significant predictor for death (HR: 0.82, 95% CI: 0.41-1.61).

Conclusion: In this study, large-artery stenosis and thoracic but not abdominal aortic complications were higher in patients with GCA. The pattern of involvement of large-artery and aortic manifestations differed in patients with GCA. Compared to the general population, the incidence of LV complications in patients with GCA increased over time which has implications for the long-term follow-up. GCA did not significantly increase risk of death in subjects with LV complications.

Supporting image 1

Table 1. Large Vessel Complications in Patients with GCA Compared to Matched Comparators without GCA.

Supporting image 2

Figure 1. Cumulative incidence trends of any LV complication (upper panel), Large artery stenosis (middle panel) and Aortic aneurysm/dissection (lower panel) diagnosed within 1 year prior to incidence/index date or anytime thereafter during follow up.


Disclosures: M. Elfishawi: None; M. Kaymakci: None; S. Achenbach: None; C. Crowson: None; T. Kermani: None; C. Weyand: None; M. Koster: None; K. Warrington: Bristol-Myers Squibb(BMS), 5, Chemocentryx, 1, 6, Eli Lilly, 5, kiniksa, 5.

To cite this abstract in AMA style:

Elfishawi M, Kaymakci M, Achenbach S, Crowson C, Kermani T, Weyand C, Koster M, Warrington K. Risk of Large Vessel Complications in Patients with Giant Cell Arteritis, a Population-based Study [abstract]. Arthritis Rheumatol. 2023; 75 (suppl 9). https://acrabstracts.org/abstract/risk-of-large-vessel-complications-in-patients-with-giant-cell-arteritis-a-population-based-study/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2023

ACR Meeting Abstracts - https://acrabstracts.org/abstract/risk-of-large-vessel-complications-in-patients-with-giant-cell-arteritis-a-population-based-study/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology